Lumen Bioscience, Inc.
Lumen Bioscience is a pioneering biotechnology company focused on discovering, developing, and manufacturing biologic drugs for highly prevalent diseases. Utilizing a unique platform that leverages spirulina for biomanufacturing, Lumen aims to significantly reduce drug development costs and timelines, making biologic therapies more accessible and affordable. The company's mission is to bring innovative medicines to patients with serious or life-threatening conditions, expanding access through scalable, low-cost biologic solutions.
Industries
Nr. of Employees
medium (51-250)
Lumen Bioscience, Inc.
Patents
Microorganisms with broadened light absorption capability and increased photosynthetic activity
US-10787488-B2
View Details
Microorganisms with broadened light absorption capability and increased photosynthetic activity
US-10787488-B2
View DetailsProducts
Oral biologic cocktail for Clostridioides difficile (clinical candidate)
Capsule-formulated multi-component biologic cocktail intended to be administered alongside standard-of-care antibiotics to improve initial clinical cure and reduce recurrence of C. difficile infection; demonstrated safety and preliminary efficacy in a sentinel clinical cohort.
Needle-free intranasal recombinant vaccine for malaria (preclinical)
Preclinical intranasal vaccine based on recombinant antigen expressed in a photosynthetic microbe and formulated for needle-free administration; demonstrated sterile protection in mouse pre-erythrocytic malaria models.
Oral biologic cocktail candidates for inflammatory bowel disease and other GI indications (preclinical)
Preclinical programs developing orally delivered multi-protein cocktails targeting Crohn’s disease, ulcerative colitis, gastroenteritis and other gastrointestinal conditions.
Oral biologic cocktail for Clostridioides difficile (clinical candidate)
Capsule-formulated multi-component biologic cocktail intended to be administered alongside standard-of-care antibiotics to improve initial clinical cure and reduce recurrence of C. difficile infection; demonstrated safety and preliminary efficacy in a sentinel clinical cohort.
Needle-free intranasal recombinant vaccine for malaria (preclinical)
Preclinical intranasal vaccine based on recombinant antigen expressed in a photosynthetic microbe and formulated for needle-free administration; demonstrated sterile protection in mouse pre-erythrocytic malaria models.
Oral biologic cocktail candidates for inflammatory bowel disease and other GI indications (preclinical)
Preclinical programs developing orally delivered multi-protein cocktails targeting Crohn’s disease, ulcerative colitis, gastroenteritis and other gastrointestinal conditions.
Services
Clinical-stage production services including indoor cultivation, spray-drying, and filling of orally or intranasally delivered recombinant biologic candidates under cGMP conditions.
Collaborative development services leveraging a photosynthetic microbe expression and spray-drying platform to discover, optimize and advance oral or intranasal biologic candidates through preclinical and early clinical stages.
Application of ML/AI to cultivation and recombinant production data to increase productivity and process control for GMP manufacturing.
Clinical-stage production services including indoor cultivation, spray-drying, and filling of orally or intranasally delivered recombinant biologic candidates under cGMP conditions.
Collaborative development services leveraging a photosynthetic microbe expression and spray-drying platform to discover, optimize and advance oral or intranasal biologic candidates through preclinical and early clinical stages.
Application of ML/AI to cultivation and recombinant production data to increase productivity and process control for GMP manufacturing.
Expertise Areas
- Oral biologic development
- Mucosal vaccine and therapeutic development (oral/intranasal)
- Photosynthetic microbe bioprocessing
- Combination antibody therapeutics
Key Technologies
- Photosynthetic microbe expression system (cyanobacterium-based)
- Chromosomal gene integration for recombinant protein expression
- Spray-drying whole-biomass formulation
- Oral capsule/tablet formulation for biologics
News & Updates
Top-line results from the RePreve Clinical Trial evaluating LMN-201 for Clostridioides difficile infection show a 100% initial clinical cure rate in the sentinel cohort, with significant reduction in recurrence and a favorable safety profile.
Lumen Bioscience has published data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria, with potential to expand access to malaria vaccines.
Lumen Bioscience announced securing $5.5 million in funding to develop needle-free vaccines, advancing its platform for affordable and accessible biologic therapeutics.
In 2022, Lumen Bioscience experienced significant growth, expanding its clinical pipeline, manufacturing facilities, and securing over $36 million in new funding, including grants and equity.
The RePreve clinical trial's sentinel cohort achieved a 100% initial clinical cure rate for C. difficile infection using LMN-201, demonstrating promising potential for this spirulina-based biologic.
Lumen's malaria vaccine, produced in spirulina, has demonstrated efficacy in providing sterile protection in mice, with potential for human application.
Top-line results from the RePreve Clinical Trial evaluating LMN-201 for Clostridioides difficile infection show a 100% initial clinical cure rate in the sentinel cohort, with significant reduction in recurrence and a favorable safety profile.
Lumen Bioscience has published data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria, with potential to expand access to malaria vaccines.
Lumen Bioscience announced securing $5.5 million in funding to develop needle-free vaccines, advancing its platform for affordable and accessible biologic therapeutics.
In 2022, Lumen Bioscience experienced significant growth, expanding its clinical pipeline, manufacturing facilities, and securing over $36 million in new funding, including grants and equity.
The RePreve clinical trial's sentinel cohort achieved a 100% initial clinical cure rate for C. difficile infection using LMN-201, demonstrating promising potential for this spirulina-based biologic.
Lumen's malaria vaccine, produced in spirulina, has demonstrated efficacy in providing sterile protection in mice, with potential for human application.